EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateJosef S Smolen, Désirée van der Heijde, Janet Pope et al.|Annals of the Rheumatic Diseases|2020Cited by 2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateJosef S Smolen, Désirée van der Heijde, Robert Landewé et al.|Annals of the Rheumatic Diseases|2022Cited by 1.9k
2022 updateJosef S Smolen, Josef S. Smolen, Robert Landewé et al.|Radboud Repository (Radboud University)|2010Cited by 1.6k
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Claire‐Anne Siegrist, Julie-Anne Dayer et al.|The Lancet Infectious Diseases|2015Cited by 278
Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population‐based cohort studyStéphane Genevay, Cem Gabay, Axel Finckh et al.|Arthritis Care & Research|2007Cited by 125